In addition to GLP-1R/GCGR dual agonists, a chimeric peptide as dual GLP-1/GIP receptor agonists has been developed, showing enhanced therapeutic potential for obesity and related comorbidities. This evidence concerns the gene GLP1R and obesity disorder.